From Science to Practice: Senzime Obtains FDA 510(k) Clearance for Enhanced TetraGraph System

Q: What FDA 510(k) clearance did Senzime (OTCQX:SNZZF) receive for the TetraGraph system in May 2026?

Senzime received an additional FDA Class II 510(k) clearance for its TetraGraph neuromuscular monitoring system. According to Senzime, this new clearance expands the system’s capabilities and supports unique features of the next-generation TetraGraph platform over time.

Q: How does Senzime’s TetraGraph neuromuscular monitoring system work during surgery?

TetraGraph uses proprietary algorithms and advanced sensors to monitor neuromuscular function during surgery. According to Senzime, it helps clinicians decide when to intubate, adjust neuromuscular blocking and reversal agent dosing, and determine when patients are ready for extubation and spontaneous breathing.

Q: In how many hospitals is Senzime’s TetraGraph system currently used worldwide?

According to Senzime, the TetraGraph system is used in more than 750 hospitals worldwide. Anesthesiologists use it to support patient safety during and after surgery by closely monitoring neuromuscular function and guiding key decisions around intubation and extubation.

Q: What benefits does the new FDA 510(k) clearance bring to Senzime’s TetraGraph competitive position?

The new clearance is described as expanding TetraGraph’s capabilities and strengthening its competitive advantages. According to Senzime, it underpins unique next-generation system features and supports innovations aimed at improving patient safety, clinical workflows, and cost-effective perioperative care.

Q: How might Senzime’s enhanced TetraGraph system impact patient safety in anesthesia?

Senzime states that TetraGraph is designed to enhance patient safety during and after surgery. By accurately tracking neuromuscular function, it can help prevent premature extubation, optimize neuromuscular drug dosing, and support safer transitions to spontaneous breathing in postoperative care.

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Senzime (OTCQX:SNZZF) has received an additional FDA Class II 510(k) clearance for its TetraGraph neuromuscular monitoring system, following an April 2026 submission.

The clearance expands the system’s capabilities and supports next-generation features. TetraGraph is used in over 750 hospitals to help anesthesiologists optimize intubation, drug dosing, and extubation decisions.

Positive

Additional FDA Class II 510(k) clearance for TetraGraph neuromuscular monitor
Clearance supports expanded capabilities and next-generation TetraGraph features
TetraGraph already used by anesthesiologists in more than 750 hospitals worldwide
System aims to enhance patient safety and improve clinical workflows in surgery

Negative

None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/27/2026 - 05:35 AM

UPPSALA, SE / ACCESS Newswire / May 27, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced that its TetraGraph^® neuromuscular monitoring system has received an additional FDA Class II 510(k) clearance. The new FDA clearance follows submission in April 2026 and expands the system's capabilities, further strengthening the TetraGraph's competitive advantages.

The new 510(k) clearance includes, among other things, unique capabilities of the next-generation TetraGraph system, and additional innovations that will be introduced over time.

"This FDA clearance is an important milestone for Senzime, enabling broadened competitive advantages of current and future capabilities of the TetraGraph system," said Philip Siberg, CEO of Senzime. "We continue to pioneer our industry by developing innovations that enhance patient safety, improve clinical workflows, and support more cost-effective care."

The TetraGraph system is used by anesthesiologists in more than 750 hospitals worldwide to support patient safety during and after surgery. The system uses proprietary algorithms and advanced sensors to accurately monitor neuromuscular function during surgery. This helps clinicians to determine when it is appropriate to intubate patients, optimize dosing of neuromuscular blocking and reversal agents, and assess when patients are ready for extubation and spontaneous breathing after surgery.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph^® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

From science to practice: Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system

SOURCE: Senzime

View the original press release on ACCESS Newswire

FAQ

What FDA 510(k) clearance did Senzime (OTCQX:SNZZF) receive for the TetraGraph system in May 2026?

Senzime received an additional FDA Class II 510(k) clearance for its TetraGraph neuromuscular monitoring system. According to Senzime, this new clearance expands the system’s capabilities and supports unique features of the next-generation TetraGraph platform over time.

How does Senzime’s TetraGraph neuromuscular monitoring system work during surgery?

TetraGraph uses proprietary algorithms and advanced sensors to monitor neuromuscular function during surgery. According to Senzime, it helps clinicians decide when to intubate, adjust neuromuscular blocking and reversal agent dosing, and determine when patients are ready for extubation and spontaneous breathing.

In how many hospitals is Senzime’s TetraGraph system currently used worldwide?

According to Senzime, the TetraGraph system is used in more than 750 hospitals worldwide. Anesthesiologists use it to support patient safety during and after surgery by closely monitoring neuromuscular function and guiding key decisions around intubation and extubation.

What benefits does the new FDA 510(k) clearance bring to Senzime’s TetraGraph competitive position?

The new clearance is described as expanding TetraGraph’s capabilities and strengthening its competitive advantages. According to Senzime, it underpins unique next-generation system features and supports innovations aimed at improving patient safety, clinical workflows, and cost-effective perioperative care.

How might Senzime’s enhanced TetraGraph system impact patient safety in anesthesia?

Senzime states that TetraGraph is designed to enhance patient safety during and after surgery. By accurately tracking neuromuscular function, it can help prevent premature extubation, optimize neuromuscular drug dosing, and support safer transitions to spontaneous breathing in postoperative care.

What clinical decisions can Senzime’s TetraGraph monitoring system support in the operating room?

According to Senzime, TetraGraph helps clinicians determine when to intubate, titrate neuromuscular blockers and reversal agents, and extubate patients. Its neuromuscular monitoring data supports more informed, timely decisions during anesthesia and recovery, potentially improving outcomes and workflow efficiency.